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The effects of dopamine ( lop5 M) on growth hormone and prolactin secretion and the fractional rate of 
86Rb efflux were investigated using perifused bovine pituitary cells. Dopamine decreased the control 
efflux rate, prevented the rise caused by thyroliberin (lo-’ M) in the presence of 3-isobutyl-l-methyl- 
xanthine ( 1O-4 M) and greatly decreased the rise caused by acetylcholine (2.5 x 10e5 M). Under these 
conditions it inhibited the prolactin secretion but it had no effect on growth hormone secretion induced by 
either treatment. Dopamine receptors in lactotrophs are therefore coupled to secretion and potassium 
permeability, but if somatotrophs contain dopamine receptors they are coupled only to K+ efflux. 




We have shown that the hypothalamic peptide 
TRH (thyroliberin) stimulates the secretion of pro- 
lactin and the efflux of *‘jRb, an isotope which be- 
haves like potassium, from perifused bovine pitui- 
tary cells in vitro [l] and that acetylcholine in- 
creases growth hormone release and *6Rb efflux 
from these cells 121. Anterior pituitary cells exhibit 
spontaneous and evoked action potentials, and it is 
possible that calcium entry during the action po- 
tentials leads to secretion since for example TRH 
increases their frequency [3]. Our data [ 1,2] suggest 
that there is a connection between potassium per- 
meability, electrical activity and growth hormone 
secretion from somatotrophs. Thus 4-amino- 
pyridine and tetraethylammonium ions, which are 
potassium channel blockers [4] and increase the 
frequency [S] and duration [6], respectively, of 
action potentials in pituitary cells, potentiate the 
secretion of growth hormone caused by TRH [l] 
and acetylcholine [2]. 
Since dopamine decreases the electrical activity of 
pituitary cells [S], the opposite effect to that of 
TRH, it is of interest to determine whether dopa- 
mine also has the opposite effect on 86Rb efflux. 
Therefore, we have investigated the effects of do- 
pamine on growth hormone and prolactin secre- 
tion and 86Rb efflux from perifused bovine pitui- 
tary cells. We report here that dopamine inhibited 
the basal fractional 86Rb efflux rate, prevented the 
rise in efflux caused by TRH in the presence of 
3-isobutyl-1-methylxanthine (IBMX), and greatly 
decreased the rise in efflux caused by acetylcho- 
line. Dopamine also inhibited prolactin secretion 
caused by TRH in the presence of IBMX and by 
acetylcholine, but had no effect on the growth hor- 
mone secretion induced by either treatment. 
Dopamine receptors in lactotrophs may therefore 
be coupled to secretion and potassium permeabili- 
ty, but if somatotrophs contain dopamine recep- 
tors they are only coupled to potassium efflux. 
Dopamine inhibits prolactin secretion in vitro 
from normal and tumour pituitary cell lines [7], 
and can also inhibit growth hormone release from 
normal and adenomatous human pituitaries [7]. 
2. MATERIALS AND METHODS 
+To whom correspondence should be addressed 
The experimental procedures were as outlined 
in [I]. Bovine anterior pituitary glands were dis- 
persed using collagenase (Boehringer; 1 mg/ml) in 
the presence of soyabean trypsin inhibitor (Sigma; 
0.3 mg/ml), and a fraction enriched in lactotrophs 
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and somatotrophs obtained by centrifugation 
through Percoll. The cells (2 x 107) were incubated 
for 90 min in 1.5 ml medium containing: *6Rb 
(100 PCi, 50 PM), NaCl (118 mM), KC1 (5.9 mM), 
KH2P04 (1.2 mM), M&12 (1.2 mM), CaCl2 
(2.5 mM), NaHC03 (21 mM), sodium 3-hydroxy- 
butyrate (1.2 mM), glucose (2.8 mM) and bovine 
serum albumin (Sigma fraction V, 1 mg/ml) and 
equilibrated with 02:COz (95:5, v/v). The cells 
were then suspended in the same medium con- 
taining no rubidium and aliquots containing 
2.5 x 106 cells were transferred to 8 columns each 
containing 0.4 ml swollen Sephadex G-10. The col- 
umns were perifused with the same medium at 
37°C and a flow rate of 0.2 ml/min, collecting 
2 min fractions. In each experiment 4 sets of condi- 
tions were performed in duplicate. The first 20 
fractions (40 min) were discarded and the next 24 
fractions were collected. Dopamine (1O-5 M) or 
IBMX (1O-4 M) were introduced after 50 min and 
TRH (lo-7 M) or acetylcholine (2.5 x 10~~ M) 
after 64 min, were appropriate. 
The concentrations of growth hormone and pro- 
lactin were determined by radioimmunoassay [ 11, 
and in order to combine the data from a number 
of experiments using different cell preparations, 
the hormone release in each channel was nor- 
malised to bring the mean rate of release during 
the control period (41-50 min) for that channel to 
1. The 86Rb content of the fractions was deter- 
mined by Cerenkov counting and normalised by 
expressing the efflux as the fraction of the total 
86Rb present in the cells at the beginning of each 
2 min period which was washed out during that 
period. 
3. RESULTS 
The effects of dopamine on the responses to 
acetylcholine are shown in Iig.1. Dopamine de- 
creased the basal fractional rate of *6Rb efflux and 
almost completely prevented the subsequent rise in 
efflux caused by acetylcholine (fig.lA). It had no 
effect on the secretion of growth hormone caused 
by acetylcholine (fig.lB), but decreased basal pro- 
lactin secretion and prevented the small rise 
caused by acetylcholine (fig. 1C). 
The effects of TRH were examined in the pres- 
ence of IBMX (1O-4 M) because this methyl- 
xanthine potentiates the increases in prolactin re- 
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Fig.1. The figure shows the fractional rate of s6Rb efflux 
(A), the rate of growth hormone secretion (B) and the 
rate of prolactin secretion (C) from perifused bovine 
pituitary cells. The first 20 two min fractions were dis- 
carded and fraction 1 in the figure therefore refers to 
material released in the 41st and 42nd min of perifusion. 
Dopamine (10-s M) was present in one channel (...o...) 
from the 50th min (fraction 6) onwards, and acetylcho- 
line (2.5 x 10-s M) was present in both channels from 
the 64th min (fraction 13) onward. Data are means and 
bars standard errors for 6 columns from 3 cell batches: 
other details are as in section 2. 
lease and cyclic AMP concentration caused by 
TRH [9] and because we have found that it also 
potentiates TRH-induced growth hormone secre- 
tion (unpublished). IBMX itself increased the frac- 
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Fig.2. Dopamine (IO-5 M) present in one channel 
(...o...) from the 50th min (fraction 6) onwards; IBMX 
(IO-4 M) was present in both channels from the 50th 
min (fraction 6) onwards and TRH (lo-’ M) was pres- 
ent in both channels from the 64th min (fraction 13) 
onwards; other details are as in fig.1 and section 2. 
tional rate of s6Rb efflux and when TRH was add- 
ed there was a further large increase in *6Rb efflux 
(tig.2A). When dopamine was added with IBMX it 
prevented the rises in efflux caused by both the 
methylxanthine and by TRH, but did not decrease 
basal efflux (fig2A). IBMX alone had little effect 
on prolactin or growth hormone secretion but in its 
presence TRH increased both growth hormone 
(fig.2B) and prolactin (lig.2C) secretion. When 
dopamine was added with IBMX, it prevented 
prolactin (lig.2C) but not growth hormone (fig.2B) 
secretion in response to TRH. 
4. DISCUSSION 
These data show that dopamine inhibits prolac- 
tin but not growth hormone secretion from bovine 
pituitary cells and that it inhibits all of the g6Rb 
efflux caused by TRH and most of that caused by 
acetylcholine. Taken at face value the implications 
are that dopamine receptors are only present on 
bovine lactotrophs and that most of the s6Rb 
efflux comes from them. Data on the presence of 
dopamine receptors on somatotrophs from other 
species are conflicting, but dopamine inhibits 
growth hormone release from human pituitaries in 
vitro 17,101 and dopamine receptors have been 
demonstrated by light microscopy on rat somato- 
trophs [ 111 even though dopamine apparently does 
not inhibit rat growth hormone secretion in vitro 
[ 121. Therefore, it is possible that dopamine recep- 
tors are usually present on somatotrophs, but that 
they are not always coupled to the inhibition of 
growth hormone secretion. 
Whether or not this is so, it is clearly possible to 
stimulate growth hormone release in vitro without 
a large associated increase in 86Rb efflux. If the 
secretion of growth hormone involves increased 
electrical activity, as the potentiation of secretion 
by 4-aminopyridine and tetraethylammonium 
would seem to indicate [ 1,2], then it follows that 
dopamine does not prevent the increase in somato- 
trophs and that very little *6Rb efflux needs to oc- 
cur during it. Moreover, dopamine did not affect 
the termination of the burst of growth hormone 
secretion even though it inhibited the majority of 
the s6Rb efflux caused by TRH in the presence of 
IBMX or by acetylcholine. Therefore, it is unlikely 
that the termination of the secretory episodes is 
brought about by increased potassium efflux, per- 
haps through calcium-activated potassium chan- 
nels 141, hyperpolarising the somatotroph plasma 
membrane and terminating calcium entry. The 
data strongly suggest that the majority of the ob- 
served 86Rb efflux is not tightly coupled to either 
the initiation or termination of growth hormone 
secretion. 
The mechanism whereby dopamine inhibits 
s6Rb efflux could be related to the mechanism by 
which it inhibits prolactin release, for which there 
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are several proposals. One proposal is that dopa- 
mine decreases the pituitary cyclic AMP concen- 
trations by inhibiting adenylate cyclase and that 
this inhibits prolactin release [ 13,141. The effects of 
dopamine and IBMX on the fractional rate of 
*6Rb efflux could be related to changes in cyclic 
AMP metabolism. If dopamine inhibited cyclic 
AMP synthesis and IBMX, by inhibiting cyclic 
AMP phosphodiesterase, inhibited cyclic AMP 
breakdown [9], their combined actions on the con- 
centration of cyclic AMP might, like their com- 
bined actions on 86Rb efflux, cancel each other 
out. An alternative proposal, supported by the 
ability of the ionophore A23 187 to overcome do- 
pamine inhibition of prolactin release [ 151, is that 
dopamine inhibits calcium entry into lactotrophs. 
The inhibition could be secondary to an alteration 
in chloride permeability affecting the functioning 
of the calcium channel as suggested in IS]. Inhibi- 
tion of calcium entry might also explain the de- 
crease in potassium efflux since a fall in the 
cytoplasmic calcium concentration could cause the 
activity of the calcium-sensitive potassium channel 
to drop [4]. This would explain the data satisfac- 
torily provided all the 86Rb efflux in the presence 
of TRH and IBMX, and most of the efflux in the 
presence of acetylcholine come from lactotrophs. 
However, dopamine cannot prevent a rise in 
cytoplasmic calcium in somatotrophs since it did 
not inhibit growth hormone secretion. Therefore if 
some of the 86Rb efflux comes from somatotrophs, 
the inhibition of that efflux by dopamine cannot 
be explained in terms of decreased calcium con- 
centration. The mechanism by which dopamine in- 
hibits s6Rb efflux, like the mechanism by which it 
inhibits prolactin release, remains to be estab- 
lished. 
ACKNOWLEDGEMENTS 
We thank the University of Bristol and the 
CVCP (UK) for financial support, F. Hills for the 
prolactin antiserum and C. Chapman for technical 

















Saith, S., Bicknell, R.J. and Schofield, J.G. (1982) 
FEBS Lett. 140, 121-123. 
Schofield, J.G. and Saith, S. (1981) Eur. J. Pharm. 
76, 43 I-434. 
Tixier-Vidal, A. and Gourdji, D. (1981) Physiol. 
Rev. 61,974-1011. 
Adams, D.J., Smith, S.J. and Thompson, S.H. 
(1980) Annu. Rev. Neurosci. 3, 141-167. 
Ozawa, S. and Kimura, N. (1979) Proc. Natl. Acad. 
Sci. USA 76,6017-6020. 
Taraskevich, P.S. and Douglas, W.W. (1980) Neu- 
roscience 5. 42 l-43 1. 
Lawton, N.F.. Evans, A.J. and Weller, R.O. (1981) 
J. Neurol. Sci. 49. 229-239. 
Dufy, B.. Vincent, J.D.. Fleury, H., Du Pasquier, P., 
Gourdji, D. and Tixier-Vidal, A. (1979) Nature 282. 
855857. 
Naor. Z., Snyder, G., Fawcett, C.P. and McCann, 
S.M. (1980) Endocrinology 106, 1304- 13 IO. 
Tallo, D. and Malarkey, W.B. (1981) J. Clin. Endo- 
crin. Metab. 53, 1278-1284. 
Goldsmith, P.C., Cronin, M.J. and Weiner, R.I. 
(1979) J. Histochem. Cytochem. 27, 1205-1207. 
Birge, C.A.. Jacobs, LX, Hammer, C.T. and 
Daughaday. W.H. (1970) Endocrinology 86, 120- 
130. 
De Camille, P., Macconi, D., and Spada, A. (1979) 
Nature 278,252-254. 
Labrie, F., Godbout, M., Beaulieu, M.. Borgeat, 
M.P. and Barden, N. (1979) Trends Biochem. Sci. 4, 
158-160. 
Thorner, M.O., Hackett, J.K., Murad, F. and 
Macleod. R.M. ( 1980) Neuroendocrinology 3 I, 
390-402. 
30 
